Kura (KURA)
Develops targeted cancer medicines led by KOMZIFTI for genetically defined AML.
$11.75
After hours0.00 (0.00%)
At close$11.75(+1.29%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 98.50% | 87.62M shares | |
|---|---|---|---|
| 227 holders · as of Jun 30, 2026 | |||
| Insiders | 2.05% | 1.83M shares | |
| 9 holders · as of Aug 24, 2026 | |||
| Adds to | 100.55% | ||
88.96M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 100.55%; nothing is left for Other.
13F, as of Jun 30, 2026
227 holders · 87.62M shares · 30 new positions · 121 increased · 64 reduced · 29 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 10.51M | 11.81% | +871.7K | Aug 7, 2026 |
| Suvretta Capital Management, LLC | 8.58M | 9.64% | 0 | Aug 14, 2026 |
| BVF Inc/IL | 8.45M | 9.49% | 0 | Aug 14, 2026 |
| State Street Corp | 5.33M | 5.99% | +817.3K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 3.92M | 4.40% | +130.5K | Aug 13, 2026 |
| Armistice Capital, LLC | 3.68M | 4.13% | −58.0K | Aug 14, 2026 |
| AQR Capital Management LLC | 3.13M | 3.51% | +1.00M | Aug 14, 2026 |
| Goldman Sachs Group Inc | 2.27M | 2.55% | +831.7K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 9.40% | 7.56M | 13G | May 2, 2025 |
| BlackRock, Inc. | 7.80% | 6.33M | 13G | Apr 17, 2025 |
| Armistice Capital, LLC | 7.14% | 6.20M | 13G | Aug 15, 2025 |
| State Street Corporation | 5.70% | 4.93M | 13G | Feb 9, 2026 |
| Peter Kolchinskyincl. RA Capital Management, L.P., RA Capital Healthcare Fund, L.P. +1 more | 5.60% | 4.37M | 13G | Dec 5, 2024 |
| Biotechnology Value Fund L P | 5.10% | 4.42M | 13G | Nov 14, 2025 |
| Vanguard Capital Management | 5.01% | 4.43M | 13G | Apr 30, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 24, 2026 | Troy Edward Wilsondirector, officer: President and CEO | Purchase | 100,000 | $12.39 | 479,194 |
| Aug 21, 2026 | Brian T. Powlofficer: Chief Commercial Officer | Sale | 4,345 | $11.89 | 169,269 |
| Aug 19, 2026 | Teresa Brophy Bairofficer: Chief Legal Officer | Sale | 31,487 | $12.63 | 195,444 |
| Aug 17, 2026 | Troy Edward Wilsondirector, officer: President and CEO | Purchase | 100,000 | $11.12 | 379,194 |
| Jun 18, 2026 | Mollie Leoniofficer: Chief Medical Officer | Sale | 84,929 | $9.82 | 182,345 |
| May 21, 2026 | Brian T. Powlofficer: Chief Commercial Officer | Sale | 10,000 | $11.00 | 173,614 |
| May 18, 2026 | Teresa Brophy Bairofficer: Chief Legal Officer | Sale | 2,256 | $9.38 | 226,931 |
| May 19, 2026 | Kathleen Fordofficer: Chief Operating Officer | Sale | 2,257 | $9.08 | 153,560 |
| May 19, 2026 | Brian T. Powlofficer: Chief Commercial Officer | Sale | 339 | $9.21 | 183,614 |
| Jan 27, 2026 | Teresa Brophy Bairofficer: Chief Legal Officer | Sale · 3 lots | 11,208 | $8.46 | 226,931 |
House and Senate disclosures
Not reported.